• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    8/3/22 6:13:35 PM ET
    $BCLI
    $CASI
    $CCRN
    $ENVB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCLI alert in real time by email

    Gainers

    • Exicure (NASDAQ:XCUR) shares increased by 97.0% to $3.92 during Wednesday's after-market session. This security traded at a volume of 1.0 million shares come close, making up 12.1% of its average volume over the last 100 days. The company's market cap stands at $19.4 million.
    • Syros Pharmaceuticals (NASDAQ:SYRS) shares rose 39.89% to $1.23. Today's trading volume for this security ended up closing at 4.8 million shares, which is 673.0 percent of its average volume over the last 100 days. The company's market cap stands at $77.4 million.
    • Motus GI Hldgs (NASDAQ:MOTS) stock moved upwards by 22.91% to $5.9. Motus GI Hldgs's trading volume hit 948.2K shares by close, accounting for 146.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $16.2 million.
    • Tyme Technologies (NASDAQ:TYME) shares rose 19.16% to $0.36. Today's trading volume for this security ended up closing at 1.8 million shares, which is 145.4 percent of its average volume over the last 100 days. The company's market cap stands at $61.9 million.
    • CASI Pharmaceuticals (NASDAQ:CASI) stock increased by 18.25% to $2.85. CASI Pharmaceuticals's trading volume hit 91.9K shares by close, accounting for 35.4% of its average volume over the last 100 days.
    • LumiraDx (NASDAQ:LMDX) shares rose 13.93% to $1.88. This security traded at a volume of 302.9K shares come close, making up 71.5% of its average volume over the last 100 days. The company's market cap stands at $584.6 million.

    Losers

    • Heart Test Laboratories (NASDAQ:HSCS) stock fell 16.5% to $2.74 during Wednesday's after-market session. Heart Test Laboratories's trading volume hit 185.9K shares by close, accounting for 74.0% of its average volume over the last 100 days. The company's market cap stands at $22.5 million.
    • Poseida Therapeutics (NASDAQ:PSTX) shares declined by 15.75% to $3.8. Poseida Therapeutics's trading volume hit 4.0 million shares by close, accounting for 1688.9% of its average volume over the last 100 days. The company's market cap stands at $238.2 million.
    • Brainstorm Cell (NASDAQ:BCLI) stock declined by 14.13% to $2.25. The market value of their outstanding shares is at $82.0 million.
    • Enveric Biosciences (NASDAQ:ENVB) shares decreased by 12.98% to $11.4. This security traded at a volume of 857.8K shares come close, making up 39.1% of its average volume over the last 100 days.
    • Cross Country Healthcare (NASDAQ:CCRN) shares declined by 10.61% to $24.53. The company's, Q2 earnings came out today.
    • Travere Therapeutics (NASDAQ:TVTX) shares decreased by 10.42% to $21.5. Trading volume for this security closed at 164.4K, accounting for 20.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.3 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BCLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCLI
    $CASI
    $CCRN
    $ENVB

    CompanyDatePrice TargetRatingAnalyst
    Cross Country Healthcare Inc.
    $CCRN
    3/19/2026$15.00Neutral → Outperform
    Wedbush
    Cross Country Healthcare Inc.
    $CCRN
    3/5/2026$14.00Hold → Buy
    The Benchmark Company
    Cross Country Healthcare Inc.
    $CCRN
    2/3/2026$11.00Neutral
    Wedbush
    Cross Country Healthcare Inc.
    $CCRN
    12/4/2025$11.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Travere Therapeutics Inc.
    $TVTX
    10/31/2025$34.00 → $48.00Buy
    Citigroup
    Travere Therapeutics Inc.
    $TVTX
    6/11/2025$30.00Buy
    H.C. Wainwright
    Travere Therapeutics Inc.
    $TVTX
    6/11/2025$35.00 → $32.00Buy
    Citigroup
    Travere Therapeutics Inc.
    $TVTX
    1/10/2025Overweight
    Cantor Fitzgerald
    More analyst ratings

    $BCLI
    $CASI
    $CCRN
    $ENVB
    SEC Filings

    View All

    HeartSciences Inc. filed SEC Form 8-K: Leadership Update

    8-K - HeartSciences Inc. (0001468492) (Filer)

    4/3/26 5:15:10 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    SEC Form PRE 14A filed by Enveric Biosciences Inc.

    PRE 14A - Enveric Biosciences, Inc. (0000890821) (Filer)

    4/3/26 5:05:48 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exicure Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - EXICURE, INC. (0001698530) (Filer)

    4/2/26 4:15:02 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $CASI
    $CCRN
    $ENVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cash W Larry bought $40,829 worth of shares (5,000 units at $8.17), increasing direct ownership by 3% to 204,632 units (SEC Form 4)

    4 - CROSS COUNTRY HEALTHCARE INC (0001141103) (Issuer)

    12/9/25 4:08:59 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    Large owner Hitron Systems Inc. bought $8,700,000 worth of shares (2,900,000 units at $3.00), increasing direct ownership by 669% to 3,333,333 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    3/26/25 5:41:19 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Cash W Larry bought $61,320 worth of shares (6,000 units at $10.22), increasing direct ownership by 3% to 199,632 units (SEC Form 4)

    4 - CROSS COUNTRY HEALTHCARE INC (0001141103) (Issuer)

    12/31/24 5:15:10 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    $BCLI
    $CASI
    $CCRN
    $ENVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update

    Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidenceCompany highlights durable long-term survival in Expanded Access Program (EAP) cohort supporting Phase 3b patient selection and inclusion criteriaNEW YORK, March 31, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2025, and provided a corporate update. "Our main priority continues to be advancing NurOwn

    3/31/26 4:01:00 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates

    Patent provides added depth to Enveric's EVM301 intellectual property portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of neuropsychiatric conditions Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that on March 17, 2026, it received U.S. Patent No. 12,577,232 ("the'232 patent") from the United States Patent and Trademark Office (USPTO) pertaining to its EVM301 Series of molecules. The EVM301 Series includes lead candidate, EB-003, being developed as potential treatments for mental health d

    3/31/26 8:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025

    Product Development Highlights: Reported positive preclinical results for lead drug candidate EB-003, showing statistically significant improvements in animal models of severe chronic depression and despair and in post-traumatic stress disorder (PTSD) Identified neuroplastogen candidates with potential to promote brain-derived neurotrophic factor (BDNF) signaling, an established therapeutic target for neurodegenerative disease Corporate and Business Development Highlights: Announced the withdrawal of the Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals against Enveric's issued U.S. Patent No. 12,138,276, which appears relevant to the bretisilocin (GM-2505) mol

    3/27/26 5:40:00 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $CASI
    $CCRN
    $ENVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Dube Eric M

    4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

    4/2/26 5:55:15 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Reed Elizabeth E

    4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

    4/2/26 5:55:13 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Krug Marc S.

    4 - CROSS COUNTRY HEALTHCARE INC (0001141103) (Issuer)

    4/2/26 4:10:01 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    $BCLI
    $CASI
    $CCRN
    $ENVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cross Country upgraded by Wedbush with a new price target

    Wedbush upgraded Cross Country from Neutral to Outperform and set a new price target of $15.00

    3/19/26 8:22:53 AM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    Cross Country upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded Cross Country from Hold to Buy and set a new price target of $14.00

    3/5/26 8:22:11 AM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    Wedbush initiated coverage on Cross Country with a new price target

    Wedbush initiated coverage of Cross Country with a rating of Neutral and set a new price target of $11.00

    2/3/26 8:08:13 AM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    $BCLI
    $CASI
    $CCRN
    $ENVB
    Leadership Updates

    Live Leadership Updates

    View All

    ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman

    ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team. David Johnson, newly appointed Chairman of ENvue, stated, "We believe ENvue is at the forefront of advanced feeding-tube placement technology, which has been validated in the market and extensively used in the clinic across 38 hospitals in the US. In my opinion, the Company's unique feeding tube placement system that utilizes advanced methods of navigation, integrated sensors and body mapping h

    12/15/25 9:00:00 AM ET
    $ENVB
    $FEED
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Cross Country Healthcare Announces CEO Transition

    Co-Founder and Chairman, Kevin C. Clark, Returns as Chief Executive Officer Cross Country Healthcare, Inc. (the "Company" and "Cross Country") (NASDAQ:CCRN) today announced that John A. Martins, the Company's President and Chief Executive Officer, has separated from the Company and ceased to serve as a member of its Board of Directors (the "Board"), effective as of December 14, 2025. The Board appointed Kevin C. Clark, the Company's current Chairman, former Chief Executive Officer, and Co-Founder, to succeed Mr. Martins as the Company's President and Chief Executive Officer. Mr. Clark will continue to serve as the Chairman of the Board. "The Board members are thrilled to have Kevin return

    12/15/25 8:15:00 AM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

    BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio ("Imagene"), of the combined company after the anticipated closing. "We are thrilled to welcome Dr. Yarema to the team. Kristin is bringing expertise to the team that will push the company, and our lead program, IMG-007, towards significant milestones," commented David Bonita, an Ikena director and a continuing board member of the combined company. "Her experience as a public company CEO and commercial leadership are valuable additions to this team.

    7/23/25 9:00:00 AM ET
    $IKNA
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    $CASI
    $CCRN
    $ENVB
    Financials

    Live finance-specific insights

    View All

    Exicure, Inc. Reports Full Year 2025 Financial Results

    REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position: Cash and cash equivalents were $3.7 million as of December 31, 2025, compared to $12.5 million as of December 31, 2024. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be required to support ongoing operations, continue the exploration of strategic alternatives, and pursue any alternatives that we identify. Research and Development (R&D) Expense: Research and development expenses were $3.3 million for the ye

    3/25/26 4:18:31 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cross Country Healthcare Announces Fourth Quarter and Full Year 2025 Financial Results

    Cross Country Healthcare, Inc. (the "Company," "Cross Country," "we," "us," and "our") (NASDAQ:CCRN) today announced financial results for its fourth quarter and full year ended December 31, 2025. SELECTED FINANCIAL INFORMATION: Dollars are in thousands, except per share amounts Q4 2025 Variance Q4 2025 vs Q4 2024 Variance Q4 2025 vs Q3 2025 Full Year 2025 Variance 2025 vs 2024 Revenue $ 236,761       (24 ) %   (5 ) % $ 1,054,293       (22 ) % Gross profit margin*   20.3   %   30

    3/4/26 4:15:00 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

    U.S. net product sales of FILSPARI reached $103 million, representing 108% growth compared to prior year period; all-time high 908 new PSFs received during the quarter U.S. net product sales of FILSPARI totaled $322 million for full year 2025; total net product sales were $410 million for full year 2025 PDUFA target action date for FILSPARI in FSGS is April 13, 2026; Company positioned for a successful commercial launch, if approved Enrollment activities have resumed for the pivotal Phase 3 HARMONY Study of pegtibatinase in classical HCU Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its fourth quarter and full year 2025 financial results and provided a corporate update.

    2/19/26 4:01:00 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $CASI
    $CCRN
    $ENVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Poseida Therapeutics Inc.

    SC 13D/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

    11/27/24 7:01:59 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

    SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

    11/14/24 5:28:08 PM ET
    $SYRS
    Biotechnology: Pharmaceutical Preparations
    Health Care